BioToxTech Co

BioToxTech Co Current Assets

The Current Assets of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 7.22 B KRW. In the previous year, Current Assets was 57.87 B KRW — a change of -87.53% (lower).

Current Assets

7.22 BKRW

YoY

-87.53%

Last updated:

Current Assets of BioToxTech Co is 2025 7.22 B KRW. Current Assets of BioToxTech Co was 2024 57.87 B KRW. It decreases by -87.53% lower compared to the previous year.

The BioToxTech Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
15.18 B KRW
Jan 1, 2019
16.61 B KRW
Jan 1, 2020
26.61 B KRW
Jan 1, 2021
36.98 B KRW
Jan 1, 2022
48.49 B KRW
Jan 1, 2023
52.07 B KRW
Jan 1, 2024
57.87 B KRW
Jan 1, 2025
7.22 B KRW
The BioToxTech Co Current Assets history
YEARCurrent AssetsYoY
7.22 BKRW-87.53%
57.87 BKRW+11.14%
52.07 BKRW+7.39%
48.49 BKRW+31.10%
36.98 BKRW+38.97%
26.61 BKRW+60.20%
16.61 BKRW+9.42%
15.18 BKRW+23.67%
12.28 BKRW-24.80%
16.33 BKRW+249.61%
4.67 BKRW-1.26%
4.73 BKRW-27.67%
6.54 BKRW-5.72%
6.93 BKRW+4.22%
6.65 BKRW-59.70%
16.51 BKRW+38.29%
11.94 BKRW+118.20%
5.47 BKRW-46.81%
10.29 BKRW+93.67%
5.31 BKRW+1.26%
5.25 BKRW+210.60%
1.69 BKRW-22.56%
2.18 BKRW+145.89%
887.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Current Assets of BioToxTech Co is 7.22 B KRW in 2025.

Current Assets of BioToxTech Co changed from 57.87 B KRW to 7.22 B KRW, representing a -87.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioToxTech Co

All Key Metrics — BioToxTech Co